Open Access
Numéro
Ann Toxicol Anal
Volume 24, Numéro 3, 2012
Page(s) 119 - 127
DOI https://doi.org/10.1051/ata/2012013
Publié en ligne 26 septembre 2012
  1. Evans DAP. N-acetyltransferase. In : Kalow W (editor) Pharmacogenetics of drug metabolism. New York : Pergamon Press, 1992 : 95–178.
  2. Kawamura AK, Graham J, Mushtaq A, Tsiftsoglou SA, Vath GM, Hanna PE, Wagner CR, Sim E. Eukaryotic arylamine N-acetyltransferase investigation of substrate specificity by high-throughput screening. Biochem Pharmacol. 2005; 69(2) : 347–359. [CrossRef] [PubMed]
  3. Nebert DW, Roe AL. Ethnic and genetic differences in metabolism genes and risk of toxicity and cancer. Sci Total Environ. 2001; 274(1–3) : 93–102. [CrossRef] [PubMed]
  4. Boukouvala S, Sim E. Structural analysis of the genes for human arylamine N-acetyltransferases and characterization of alternative transcripts. Basic Clin Pharmacol Toxicol. 2005; 96(5) : 343–351. [CrossRef] [PubMed]
  5. Grant DM, Blum M, Beer M, Myer UA. Monomorphic and polymorphic human arylamine N-acetyltransferases : a comparison of liver isozymes and expressed products of two cloned genes. Mol Pharmacol. 1991; 39(2) : 184–191. [PubMed]
  6. Hickman D, Pope J, Patil SD, Fakis G, Smelt V, Stanley LA, Payton M, Unadkat JD, Sim E. Expression of arylamine N-acetyltransferase in human intestine. Gut. 1998; 42(3) : 402–409. [CrossRef] [PubMed]
  7. Parkin DP, Vandenplas S, Botha FJ, Vandenplas ML, Seifart HI, van Helden PD, van der Walt BJ, Donald PR, van Jaarsveld PP. Trimodality of isoniazid elimination : phenotype and genotype in patients with tuberculosis. Am J Respir Crit Care Med. 1997; 155(5) : 1717–1722. [CrossRef] [PubMed]
  8. Smith CA, Wadelius M, Gough AC, Harrison DJ, Wolf CR, Rane A. A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid. J Med Genet. 1997; 34(9) : 758–760. [CrossRef] [PubMed]
  9. Grant DM, Hughes NC, Janezic SA, Goodfellow GH, Chen HJ, Gaedigk A, Yu VL, Grewal R. Human acetyltransferase polymorphisms. Mutat Res. 1997; 376(1-2) : 61–70. [CrossRef] [PubMed]
  10. Cascorbi I, Brockmöller J, Mrozikiewicz PM, Müller A, Roots I. Arylamine N-acetyltransferase activity in man. Drug Metab Rev. 1999; 31(2) : 489–502. [CrossRef] [PubMed]
  11. Hein DW. Molecular genetics and function of NAT1 and NAT2 : role in aromatic amine metabolism and carcinogenesis. Mutat Res. 2002; 506-507 : 65–77. [CrossRef] [PubMed]
  12. Evans DAP. Survey of the human acetylator polymorphism in spontaneous disorders. J Med Genet. 1984; 21 : 243–253. [CrossRef] [PubMed]
  13. Clark DW. Genetically determined variability in acetylation and oxidation. Therapeutic implications. Drugs. 1985; 29 : 342–375.
  14. Evans DAP. N-acetyltransferase. In : Genetic Factors in Drug Therapy. Cambridge University Press : Cambridge, 1993 : 211–302.
  15. Weber WW. Pharmacogenetics. Oxford Monographs on Medical Genetics. Oxford University Press : New York, 1997, Vol 15.
  16. Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH, Devanaboyina US, Niangju NA, Feng Y. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomark Prev. 2000; 9 : 29–42.
  17. Agundez JAG, Golka K, Martınez C, Selinski S, Blaszkewicz M, Garcia-Martin E. Unraveling ambiguous NAT2 genotyping data. Clin Chem. 2008; 54(8) : 1390–1394. [CrossRef] [PubMed]
  18. Kato R. Metabolic activation of mutagenic heterocyclic aromatic amines from protein pyrolysates. Crit Rev Toxicol. 1986; 16(4) : 307–348. [CrossRef] [PubMed]
  19. Hein DW. Acetylator genotype and arylamine-induced carcinogenesis. Biochim Biophys Acta. 1988; 948(1) : 37–66. [PubMed]
  20. Minchin RF, Reeves PT, Teitel CH, McManus ME, Mojarrabi B, Ilett KF, Kadlubar FF. N- and O-acetylation of aromatic and heterocyclic amine carcinogens by human monomorphic and polymorphic acetyltransferases expressed in COS-1 cells. Biochem Biophys Res Commun. 1992; 185(3) : 839–844. [CrossRef] [PubMed]
  21. Hein DW, Doll MA, Rustan TD, Gray K, Feng Y, Ferguson RJ, Grant DM. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis. 1993; 14 : 1633–1638. [CrossRef] [PubMed]
  22. Zenser TV, Lakshmi VM, Rustan TD, Doll MA, Deitz AC, Davis BB, Hein DW. Human N-acetylation of benzidine : role of NAT1 and NAT2. Cancer Res. 1996; 56 : 3941–3947. [PubMed]
  23. Grant DM, Tang BK, Kalow W. A simple test for acetylator phenotype using caffeine. 1984. Br J Clin Pharmacol. 2004; 58(7) : S788–S793; discussion S794–S795. [CrossRef] [PubMed]
  24. Sabbagh N, Delaporte E, Marez D, Lo-Guidice J, Piette F, Broly F. NAT2 genotyping and efficacy of sulfasalazine in patients with chronic discoid lupus erythematosus. Pharmacogenetics. 1997; 7(2) : 131–135. [CrossRef] [PubMed]
  25. Spielberg SP. N-acetyltransferases : pharmacogenetics and clinical consequences of polymorphic drug metabolism. J Pharmacokinet Biopharm. 1996; 24 : 509–519. [CrossRef] [PubMed]
  26. Kilbane AJ, Silbart LK, Manis M, Beitins IZ, Weber WW. Human N-acetylation genotype determination with urinary caffeine metabolites. Clin Pharmacol Ther. 1990; 47 : 470–477. [CrossRef] [PubMed]
  27. Evans DAP. N-acetyltransferase. Pharmacol Ther. 1989; 42 : 157–234. [CrossRef] [PubMed]
  28. Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB, Teitel CH, Massengill JP, Lawsen MF, Kadlubar FF. Determination of CYP1A2 and NAT 2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics. 1992; 2(3) : 116–127. [CrossRef] [PubMed]
  29. Hildebrand M, Seifert W. Determination of acetylator phenotype in Caucasians with caffeine. Eur J Clin Pharmacol. 1989; 37 : 525–526. [CrossRef] [PubMed]
  30. Tang BK, Kadar D, Qian L, Iriah J, Yip J, Kalow W. Caffeine as a metabolic probe : Validation of its use for acetylator phenotyping. Clin Pharmacol Ther. 1991; 49(6) : 648–657. [CrossRef] [PubMed]
  31. Grant DM, Tang BK, Kalow W. A simple test for acetylator phenotype using caffeine. Br J Clin Pharmacol. 1984; 17 : 459–464. [CrossRef] [PubMed]
  32. Tang BK, Zubovits T andKalow W. Determination of acetylated caffeine metabolites by high-performance exclusion chromatography. J Chromatogr. 1986; 375 : 170–173. [CrossRef]
  33. Grant DM, Tang BK, Kalow W. Variability in caffeine metabolism. Clin Pharmacol Ther. 1983; 33 : 591–601. [CrossRef] [PubMed]
  34. Miners JO, Birkett JD. The use of caffeine as a metabolic probe for human drug metabolizing enzymes. Gen Pharmacol. 1996; 27(2) : 245–249. [CrossRef] [PubMed]
  35. Pariente-Khayat A, Rey E, Gendrel D, Vauzelle-Kervrotdan F, Crémier O, Athis P, Badoual J, Olive G, Pons G. Isoniazid acetylation metabolic ratio during maturation in children. Clin Pharmacol Ther. 1997; 62(4) : 377–384. [CrossRef] [PubMed]
  36. Kaufmann GR, Wenk M, Taeschner W, Peterli B, Gyr K, Meyer UA, Haefeli WE. N-acetyltransferase 2 polymorphism in patients infected with human immunodeficiency virus. Clin Pharmacol Ther. 1996; 60 : 62–67. [CrossRef] [PubMed]
  37. Agence nationale de la statistique et de la démographie du Sénégal. Juin 2008. Résultats définitifs du troisième recensement général de la population et de l’habitat, 2002 : 163 p.
  38. Signorello LB, Nordmark A, Granath F, Blot WJ, McLaughlin JK, Anneren G, Lundgren S, Ekbom A, Rane A, Cnattingius S. Caffeine metabolism and the risk of spontaneous abortion of normal karyotype fetuses. Obstet Gynecol. 2001; 98(6) : 1059–1066. [CrossRef] [PubMed]
  39. Cnattingius S, Signorello LB, Annerén G, Clausson B, Ekbom A, Ljunger E, Blot WJ, McLaughlin JK, Petersson G, Rane A, Granath F. Caffeine intake and the risk of first-trimester spontaneous abortion. N Engl J Med. 2000; 43(25) : 1839–1845. [CrossRef]
  40. Fernandes O, Sabharwal M, Smiley T, Pastuszak A, Koren G, Einarson T. Moderate to heavy caffeine consumption during pregnancy and relationship to spontaneous abortion and abnormal fetal growth : a meta-analysis. Reprod Toxicol. 1998; 12(4) : 435–444. [CrossRef] [PubMed]
  41. Evans DAP, Manley KA, Mc Kusick VA. Genetic control of isoniazid metabolism in man. Br Med J. 1960; 13 : 485–491. [CrossRef]
  42. Farah F, Taylor W, Rawlins MD, James O. Hepatic drug acetylation and oxidation : effects of aging in man. Br Med J. 1977; 2 : 155–156. [CrossRef] [PubMed]
  43. Philip PA, Gayed SL, Rogers HJ, Crome P. Influence of age, sex and body weight on the dapsone acetylation phenotype. Br J Clin Pharmacol. 1987; 23 : 709–713. [CrossRef] [PubMed]
  44. Evans DA, White TA. Human acetylation polymorphism. J Lab Clin Med. 1964; 63 : 394–403. [PubMed]
  45. Gelber R, Peters J, Gordon G, Glazko A, Levy L. The polymorphic acetylation of dapsone in man. Clin Pharmacol Ther. 1971; 12 : 225–238. [PubMed]
  46. Schroder H. Simplified method for determining acetylator phenotype. Br Med J. 1972; 3 : 506–507. [CrossRef] [PubMed]
  47. Reidenberg MM, Drayer DE, Levy M, Warner H. Polymorphic acetylation procainamide in man. Clin Pharmacol Ther. 1975; 17 : 722–730. [PubMed]
  48. Rao KVN, Mitchison DA, Nair NGK, Prema K, Tripaty SP. Sulphadimidine acetylation test for classification of patients as slow and rapid inactivators of isoniazid. Br Med J. 1970; 3 : 495–497. [CrossRef] [PubMed]
  49. Rasmussen BB, Kim B. Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans. Ther Drug Monit. 1996; 18(3) : 254–262. [CrossRef] [PubMed]
  50. Allorge D, Loriot MA. La pharmacogénétique ou la promesse d’une médecine personnalisée : variations du métabolisme et du transport des médicaments. Ann Biol Clin. 2004; 62(5) : 499–511.
  51. Bakayev VV, Mohammadi F, Bahadori M, Sheikholslami M, Javeri A, Masjedi MR, Velayati AA. Arylamine N-acetyltransferase 2 slow acetylator polymorphisms in unrelated Iranian individuals. Eur J Clin Pharmacol. 2004; 60 : 467–471. [CrossRef] [PubMed]
  52. Yu MC, Skipper PL, Taghizadeh K, Tannenbaum SR, Chan KK, Henderson BE, Ross RK. Acetylator phenotype, aminobiphenyl-hemoglobin adduct levels, and bladder cancer risk in white, black, and Asian men in Los Angeles, California. J Natl Cancer Inst. 1994; 86 : 712–716. [CrossRef] [PubMed]
  53. Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol. 1997; 37 : 269–296. [CrossRef] [PubMed]
  54. Gross M, Kruisselbrink T, Anderson K, Lang N, McGovern P, Delongchamp R, Kadlubar F. Distribution and concordance of N-acetyltransferase genotype and phenotype in an American population. Cancer Epidemiol Biomarkers Prev. 1999; 8 : 683–692. [PubMed]
  55. Braz Vieira da Silva Fontes Z, Vincent-Viry M, Gueguen R,Galteau MM, Siest G. Acetylation phenotypes and biological variation in a french Caucasian population. Eur J Clin Chem Clin Biochem. 1993; 31(2) : 59–68. [PubMed]
  56. O’Neil WM, Drobitch RK, MacArthur RD, Farrough MJ, Doll MA, Fretland J, Hein DW, Crane LR, Svensson CK. Acetylator phenotype and genotype in patients infected with HIV : discordance between methods for phenotype determination and genotype. Pharmacogenetics. 2000; 10 : 171–182. [CrossRef] [PubMed]
  57. Khelil M, Tayebi B, Djerdjouri B. Polymorphisme d’acétylation de la caféine chez une population algérienne. J Soc Alger Chim. 2007; 17(1) : 65–76.
  58. Nhachi CFB. Polymorphic acetylation of sulphamethazine in a Zimbabwe population. J Med Genet. 1988; 25 : 29–31. [CrossRef] [PubMed]
  59. Hashem N, Khalifa S, Nour A. The frequency of isoniazid acetylase enzyme deficiency among Egyptians. Am J Phys Anthrop. 1969; 31 : 97–102. [CrossRef]
  60. Deguchi T, Mashimo M, Suzuki T. Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver. J Biol Chem. 1990; 265(22) : 12757–12760. [PubMed]
  61. Abzalov RA, Nigmatullina RR, Khairullina GN, Garmonov SY, Shakirova LS, Evgenev MI. Effect of physical training on Sulphamethazine acetylation rate. Bull Exp Biol Med. 2000; 130(12) :1141–1143. [PubMed]
  62. Sabbagh A, Darlu P, Crouau-Roy B, Poloni ES. Arylamine N-acetyltransferase 2 (NAT2) genetic diversity and traditional subsistence : A Worldwide Population Survey. PLoS ONE. 2011; 6(4) : 10. [CrossRef]
  63. Muscat JE, Pittman B, Kleinman W, Lazarus P, Stellman SD, Richie Jr JP. Comparison of CYP1A2 and NAT2 Phenotypes between Black and White Smokers. Biochem Pharmacol. 2008; 76(7) : 929–937. [CrossRef] [PubMed]
  64. Dandara C, Masimirembwaa CM, Magimbab A, Kaayab S, Sayib J, Sommersb DK, Snymanc JR, Haslera JA. Arylamine N-acetyltransferase (NAT2) genotypes in Africans : the identification of a new allele with nucleotide changes 481C>T and 590G>A. Pharmacogenetics. 2003; 13 : 55–58. [CrossRef] [PubMed]
  65. Loriot MA, Beaune P. La pharmacogénétique : le lien entre gènes et réponse aux médicaments. Méd Sci. 2004; 20 : 634–636.
  66. Guengerich FP. Metabolic activation of carcinogens. Pharmacol Ther. 1992; 54 : 17–61. [CrossRef] [PubMed]
  67. Lauterburg BH, Smith CV, Todd EL, Mitchell JR. Oxidation of hydrazine metabolites formed from isoniazid. Clin Pharmacol Ther. 1985; 38 : 566–571. [CrossRef] [PubMed]
  68. Noda A, Hsu KY, Noda H, Yamamoto Y, Kurozumi T. Is isoniazid-hepatotoxicity induced by the metabolite, hydrazine? J Uoeh. 1983; 5 : 183–190.